Abstract #2236

Ultra-high field MR spectroscopic imaging at 7 Tesla in Multiple Sclerosis: myo-Inositol as early biomarker for MS pathologies

Alexandra Lipka^1,2, Eva Heckova¹, Assunta Dal-Bianco³, Gilbert Hangel¹, Bernhard Strasser¹, Stanislav Motyka¹, Lukas Hingerl¹, Paulus Rommer³, Fritz Leutmezer³, Petra Hnilicová⁴, Ema Kantorová⁴, Stephan Gruber¹, Siegfried Trattnig^1,2, and Wolfgang Bogner^1,2

¹High Field MR Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ²Christian Doppler Laboratory for Clinical Molecular MR Imaging, Vienna, Austria, ³Department of Neurology, Medical University of Vienna, Vienna, Austria, ⁴Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia

Routine T1/T2-weighted magnetic resonance imaging (MRI) is the method of choice for diagnosis and treatment monitoring of Multiple Sclerosis (MS), but is not being able to map the underlying pathological processes. In contrast to T1/T2-lesions which represent the general macroscopic tissue damage, MR Spectroscopic Imaging (MRSI) can detect pathologies on a biochemical level. In 54 relapsing-remitting (RRMS) patients and 16 healthy age/sex-matched controls, we show - enabled through ultra-high resolution Free Induction Decay(FID)-MRSI at 7T - the metabolic distribution within lesions and their close proximity as well as the importance of myo-Inositol as an imaging biomarker in early lesion development.

This abstract and the presentation materials are available to members only; a login is required.

Join Here